BRCA1/2 mutations and homologous recombination deficiency (HRD) have been established as predictive biomarkers of the benefit from platinum-based chemotherapy and PARPi. Here, BRCA1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.